TY - JOUR
T1 - Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan
AU - Takahashi, Satoshi
AU - Hamasuna, Ryoichi
AU - Yasuda, Mitsuru
AU - Ishikawa, Kiyohito
AU - Hayami, Hiroshi
AU - Uehara, Shinya
AU - Yamamoto, Shingo
AU - Minamitani, Shinichi
AU - Kadota, Junichi
AU - Iwata, Satoshi
AU - Kaku, Mitsuo
AU - Watanabe, Akira
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Masumori, Naoya
AU - Kiyota, Hiroshi
AU - Egawa, Shin
AU - Tanaka, Kazushi
AU - Arakawa, Soichi
AU - Fujisawa, Masato
AU - Kumon, Hiromi
AU - Wada, Koichiro
AU - Kobayashi, Kanao
AU - Matsubara, Akio
AU - Matsumoto, Tetsuro
AU - Eto, Masatoshi
AU - Tatsugami, Katsunori
AU - Kuroiwa, Kentaro
AU - Ito, Kenji
AU - Hosobe, Takahide
AU - Hirayama, Hideo
AU - Narita, Harunori
AU - Yamaguchi, Takamasa
AU - Ito, Shin
AU - Sumii, Toru
AU - Kawai, Shuichi
AU - Kanokogi, Mototsugu
AU - Kawano, Hiromi
AU - Chokyu, Hirofumi
AU - Uno, Satoshi
AU - Monden, Koichi
AU - Kaji, Shinichi
AU - Kawahara, Motoshi
AU - Takayama, Kazuo
AU - Ito, Masayasu
AU - Yoshioka, Masaru
AU - Kano, Motonori
AU - Konishi, Takatoshi
AU - Kadena, Hitoshi
AU - Nishi, Shohei
AU - Nishimura, Hirofumi
AU - Yamauchi, Takamine
AU - Maeda, Shinichi
AU - Horie, Masanobu
AU - Ihara, Hideari
AU - Matsumura, Masaru
AU - Shirane, Takeshi
AU - Takeyama, Koh
AU - Akiyama, Kikuo
AU - Takahashi, Koichi
AU - Ikuyama, Toshihiro
AU - Inatomi, Hisato
AU - Yoh, Mutsumasa
N1 - Funding Information:
Shin Ito has received research funding from Wako Pure Chemical Industries, Ltd.
Funding Information:
Akira Watanabe has received speaker's honorarium from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., donation from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., payments for a manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd., and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. Toyama Chemical Co., Ltd., FUJIFILM Pharma Co., Ltd. and Meiji Seika Pharma Co., Ltd.
Funding Information:
Ryoichi Hamasuna has received donation from Daiichi Sankyo Co., Ltd., and research funding from Eidia Co., Ltd.
Funding Information:
Masatoshi Eto has received research funding from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Nippon Kayaku Co., Ltd., Sanofi K.K. and Eli Lilly Japan K.K., and honoraria from Shionogi & Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Glaxo SmithKline K.K., Bayer Yakuhin, Ltd., Sanofi K.K. and Takeda Pharmaceutical Co., Ltd., and has consulting/advisory roles for Novartis Pharma, Pfizer Japan Inc. and Bristol-Myers Squibb K.K.
Publisher Copyright:
© 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Genital chlamydial infection is a principal sexually transmitted infection worldwide. Chlamydia trachomatis can cause male urethritis, acute epididymitis, cervicitis, and pelvic inflammatory disease as sexually transmitted infections. Fortunately, homotypic resistant C. trachomatis strains have not been isolated to date; however, several studies have reported the isolation of heterotypic resistant strains from patients. In this surveillance study, clinical urethral discharge specimens were collected from patients with urethritis in 51 hospitals and clinics in 2009 and 38 in 2012. Based on serial cultures, the minimum inhibitory concentration (MIC) could be determined for 19 isolates in 2009 and 39 in 2012. In 2009 and 2012, the MICs (MIC90) of ciprofloxacin, levofloxacin, tosufloxacin, sitafloxacin, doxycycline, minocycline, erythromycin, clarithromycin, and azithromycin were 2 μg/ml and 1 μg/ml, 0.5 μg/ml and 0.5 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.063 μg/ml and 0.063 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.016 μg/ml and 0.016 μg/ml, and 0.063 μg/ml and 0.063 μg/ml, respectively. In summary, this surveillance project did not identify any resistant strain against fluoroquinolone, tetracycline, or macrolide agents in Japan.
AB - Genital chlamydial infection is a principal sexually transmitted infection worldwide. Chlamydia trachomatis can cause male urethritis, acute epididymitis, cervicitis, and pelvic inflammatory disease as sexually transmitted infections. Fortunately, homotypic resistant C. trachomatis strains have not been isolated to date; however, several studies have reported the isolation of heterotypic resistant strains from patients. In this surveillance study, clinical urethral discharge specimens were collected from patients with urethritis in 51 hospitals and clinics in 2009 and 38 in 2012. Based on serial cultures, the minimum inhibitory concentration (MIC) could be determined for 19 isolates in 2009 and 39 in 2012. In 2009 and 2012, the MICs (MIC90) of ciprofloxacin, levofloxacin, tosufloxacin, sitafloxacin, doxycycline, minocycline, erythromycin, clarithromycin, and azithromycin were 2 μg/ml and 1 μg/ml, 0.5 μg/ml and 0.5 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.063 μg/ml and 0.063 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.125 μg/ml and 0.125 μg/ml, 0.016 μg/ml and 0.016 μg/ml, and 0.063 μg/ml and 0.063 μg/ml, respectively. In summary, this surveillance project did not identify any resistant strain against fluoroquinolone, tetracycline, or macrolide agents in Japan.
UR - http://www.scopus.com/inward/record.url?scp=84979075835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979075835&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2016.06.010
DO - 10.1016/j.jiac.2016.06.010
M3 - Article
C2 - 27452428
AN - SCOPUS:84979075835
SN - 1341-321X
VL - 22
SP - 581
EP - 586
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 9
ER -